Capricor Therapeutics Future Growth
Future criteria checks 5/6
Capricor Therapeutics is forecast to grow earnings and revenue by 67.6% and 53.2% per annum respectively while EPS is expected to grow by 68.4% per annum.
Key information
67.6%
Earnings growth rate
68.4%
EPS growth rate
| Biotechs earnings growth | 42.7% |
| Revenue growth rate | 53.2% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 21 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 113 | 18 | -57 | -45 | 6 |
| 12/31/2025 | 38 | -40 | -72 | -61 | 7 |
| 12/31/2024 | 21 | -39 | -20 | -19 | 7 |
| 9/30/2024 | 23 | -34 | -38 | -37 | N/A |
| 6/30/2024 | 27 | -28 | -36 | -34 | N/A |
| 3/31/2024 | 27 | -24 | -33 | -31 | N/A |
| 12/31/2023 | 25 | -22 | -28 | -26 | N/A |
| 9/30/2023 | 14 | -29 | -23 | -21 | N/A |
| 6/30/2023 | 9 | -29 | -21 | -18 | N/A |
| 3/31/2023 | 6 | -29 | -18 | -15 | N/A |
| 12/31/2022 | 3 | -29 | 2 | 5 | N/A |
| 9/30/2022 | 2 | -27 | 4 | 6 | N/A |
| 6/30/2022 | N/A | -25 | 7 | 9 | N/A |
| 3/31/2022 | 0 | -23 | 9 | 11 | N/A |
| 12/31/2021 | 0 | -20 | -18 | -17 | N/A |
| 9/30/2021 | 0 | -18 | -16 | -15 | N/A |
| 6/30/2021 | 0 | -18 | -15 | -15 | N/A |
| 3/31/2021 | 0 | -17 | -13 | -12 | N/A |
| 12/31/2020 | 0 | -14 | -11 | -10 | N/A |
| 9/30/2020 | 0 | -11 | -8 | -8 | N/A |
| 6/30/2020 | 1 | -9 | -7 | -7 | N/A |
| 3/31/2020 | 1 | -7 | -6 | -6 | N/A |
| 12/31/2019 | 1 | -8 | -7 | -7 | N/A |
| 9/30/2019 | 1 | -9 | -9 | -9 | N/A |
| 6/30/2019 | 2 | -12 | -10 | -10 | N/A |
| 3/31/2019 | 2 | -14 | -12 | -12 | N/A |
| 12/31/2018 | 2 | -15 | -14 | -14 | N/A |
| 9/30/2018 | 1 | 0 | -13 | -13 | N/A |
| 6/30/2018 | 2 | 2 | N/A | -13 | N/A |
| 3/31/2018 | 2 | 2 | N/A | -13 | N/A |
| 12/31/2017 | 3 | 2 | N/A | -14 | N/A |
| 9/30/2017 | 3 | -14 | N/A | -15 | N/A |
| 6/30/2017 | 4 | -17 | N/A | -14 | N/A |
| 3/31/2017 | 4 | -18 | N/A | -15 | N/A |
| 12/31/2016 | 4 | -19 | N/A | -14 | N/A |
| 9/30/2016 | 4 | -18 | N/A | -15 | N/A |
| 6/30/2016 | 5 | -15 | N/A | -16 | N/A |
| 3/31/2016 | 5 | -14 | N/A | -13 | N/A |
| 12/31/2015 | 6 | -13 | N/A | -11 | N/A |
| 9/30/2015 | 6 | -11 | N/A | -9 | N/A |
| 6/30/2015 | 6 | -10 | N/A | -8 | N/A |
| 3/31/2015 | 6 | -8 | N/A | -12 | N/A |
| 12/31/2014 | 5 | -6 | N/A | 1 | N/A |
| 9/30/2014 | 3 | -9 | N/A | 3 | N/A |
| 6/30/2014 | 2 | -9 | N/A | 1 | N/A |
| 3/31/2014 | 1 | -9 | N/A | 6 | N/A |
| 12/31/2013 | 1 | -9 | N/A | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4LN2 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).
Earnings vs Market: 4LN2 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 4LN2 is expected to become profitable in the next 3 years.
Revenue vs Market: 4LN2's revenue (53.2% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: 4LN2's revenue (53.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 4LN2's Return on Equity is forecast to be high in 3 years time